The Neuren Pharmaceuticals share price is up 100% in 3 months: Can it keep rising?

This pharma share had a transformational year in 2023. Where next for its shares?

| More on:
Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is pushing higher on Tuesday.

In morning trade, the pharmaceutical company's shares are up 1.5% to $23.45.

This latest gain means that its shares are now up an incredible 48% in the space of a month and 100% in just three months.

Why is the Neuren Pharmaceuticals share price on fire?

Investors have been fighting to get hold of the company's shares in recent months for a number of reasons.

One is the significant early success of its Daybue product for the treatment of Rett syndrome in adult and paediatric patients two years of age and older.

It developed the product and then signed over the rights to Acadia Pharmaceuticals (NASDAQ: ACAD). This means it can focus on other developments and watch the royalties and milestone payments come in. And they certainly were flooding in during 2023!

During the third quarter of 2023, Arcadia reported net sales of Daybue in the United States of US$66.9 million. It also provided guidance for fourth-quarter net sales of between US$80 million and US$87.5 million.

This meant royalty payments of A$10.4 million in the third quarter and forecast royalties of A$12.5 to A$13.7 million for the fourth quarter, which will bring its full-year royalties to between A$26 million and A$28 million.

But management isn't resting on its laurels. It is developing new products for unmet needs that could give its earnings a major boost.

One of which, NNZ-2591, has shown significant promise in the treatment of Phelan-McDermid syndrome. And with no approved treatment for the condition currently, this bodes well for those living with the syndrome and shareholders.

Bell Potter responded very positively to the trial results for NNZ-2591. It commented:

We have far greater confidence in NNZ-2591 following the Phase 2 results and therefore materially increase our Probability of Success in PMS and the other three indications which are similarly characterised disorders.

Can its shares keep rising?

While the huge returns may now be behind us, Bell Potter sees scope for the Neuren Pharmaceuticals share price to keep rising.

Its analysts have a buy rating and a $27 price target on its shares. This implies a potential upside of 15.2% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »